Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8N2H3

UPID:
PYRD2_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N2H3; D3DR61; Q5TAA9; Q9BRQ1

BACKGROUND:
The protein Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2, with the unique identifier Q8N2H3, functions as a probable oxidoreductase. It is implicated in the regulation of mitochondrial function, highlighting its significance in cellular energy dynamics and metabolic processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Pyridine nucleotide-disulfide oxidoreductase domain-containing protein 2 offers promising avenues for therapeutic intervention. Given its regulatory role in mitochondrial function, it may be key to addressing mitochondrial-related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.